Wedbush Downgrades Fate Therapeutics (FATE) to Neutral
Tweet
Share
E-mailGet Alerts FATE Hot Sheet
Price: $2.57 +1.98%
Rating Summary:
11 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush analyst David Nierengarten downgraded Fate Therapeutics (NASDAQ: FATE) from Outperform to Neutral with a price target of $88.00.
For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.
Shares of Fate Therapeutics closed at $86.27 yesterday.
You May Also Be Interested In
- Fate Therapeutics (FATE) PT Raised to $3.50 at Wells Fargo
- Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
- Barclays Downgrades Murphy Oil Corp. (MUR) to Underweight
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
